Reader response: Undetermined stroke genesis and hidden cardiomyopathies determined by cardiac magnetic resonance
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We read with interest the article by Fonseca et al.,1 which described the frequency of previously undiagnosed cardiomyopathies in patients with ischemic stroke misclassified as having an undetermined etiology after standard diagnostic workup. The study highlights cardiomyopathies as a potential cause of “cryptogenic” stroke and takes a step forward in understanding embolic strokes of undetermined source (ESUS). First, there is accruing evidence that ESUS constitute a Pandora's box characterized by high heterogeneity in etiology, clinical presentation, and outcome.2 Second, occult embolic sources—including paroxysmal atrial fibrillation, atrial cardiopathy, left ventricular disease, cardiac valvulopathies, nonstenosing cervical or intracranial plaques, patent foramen ovale, and cancer—are associated with differences in vascular risk factors, clinical, and neuroimaging features.3,4 Third, there is major overlap of potential embolic sources in patients with ESUS, and this may help explain the negative results of the recent large randomized controlled trials of secondary prevention.5 Accordingly, a research project aimed at providing a comprehensive analysis of ESUS data—by exploring the relationships between baseline variables, including demographics, stroke severity and location, embolic sources, and their surrogate biomarkers—might allow identification of distinct phenotypes based on the underlying pathogenesis and offer a rationale for tailored strategies.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.